A citation-based method for searching scientific literature

Jasmin Jo, Martin J van den Bent, Burt Nabors, Patrick Y Wen, David Schiff. Neuro Oncol 2022
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.
Michael Weller, Martin van den Bent, Matthias Preusser, Emilie Le Rhun, Jörg C Tonn, Giuseppe Minniti, Martin Bendszus, Carmen Balana, Olivier Chinot, Linda Dirven,[...]. Nat Rev Clin Oncol 2021
321
100

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.
Adriana Olar, Khalida M Wani, Kristin D Alfaro-Munoz, Lindsey E Heathcock, Hinke F van Thuijl, Mark R Gilbert, Terri S Armstrong, Erik P Sulman, Daniel P Cahill, Elizabeth Vera-Bolanos,[...]. Acta Neuropathol 2015
208
50

Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.
Yu Fujii, Yoshihiro Muragaki, Takashi Maruyama, Masayuki Nitta, Taiichi Saito, Soko Ikuta, Hiroshi Iseki, Kazuhiro Hongo, Takakazu Kawamata. J Neurosurg 2018
36
50

A vaccine targeting mutant IDH1 in newly diagnosed glioma.
Michael Platten, Lukas Bunse, Antje Wick, Theresa Bunse, Lucian Le Cornet, Inga Harting, Felix Sahm, Khwab Sanghvi, Chin Leng Tan, Isabel Poschke,[...]. Nature 2021
103
50

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Parker L Sulkowski, Christopher D Corso, Nathaniel D Robinson, Susan E Scanlon, Karin R Purshouse, Hanwen Bai, Yanfeng Liu, Ranjini K Sundaram, Denise C Hegan, Nathan R Fons,[...]. Sci Transl Med 2017
305
50

Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.
Stephanie E Combs, Christoph Thilmann, Lutz Edler, Jürgen Debus, Daniela Schulz-Ertner. J Clin Oncol 2005
225
50

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Ilaria Maggio, Raffaele Lodi, Alba Ariela Brandes. Mol Diagn Ther 2021
9
50

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
Jason Beiko, Dima Suki, Kenneth R Hess, Benjamin D Fox, Vincent Cheung, Matthew Cabral, Nicole Shonka, Mark R Gilbert, Raymond Sawaya, Sujit S Prabhu,[...]. Neuro Oncol 2014
285
50

Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.
Ingo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, Elizabeth Maher, Macarena I De La Fuente, Matthias Holdhoff, Gregory M Cote, Howard Burris, Filip Janku, Robert J Young,[...]. J Clin Oncol 2020
91
50

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Pieter Wesseling, Daniel J Brat, Ian A Cree, Dominique Figarella-Branger, Cynthia Hawkins, H K Ng, Stefan M Pfister, Guido Reifenberger,[...]. Neuro Oncol 2021
50

The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study.
Xiaojie Ding, Zheng Wang, Di Chen, Yinyan Wang, Zheng Zhao, Chongran Sun, Dikang Chen, Chao Tang, Ji Xiong, Lingchao Chen,[...]. J Neurooncol 2018
20
50

Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).
Pierina Navarria, Giuseppe Minniti, Elena Clerici, Stefano Tomatis, Valentina Pinzi, Patrizia Ciammella, Marco Galaverni, Dante Amelio, Daniele Scartoni, Silvia Scoccianti,[...]. J Neurooncol 2019
26
50

Analysis of the IDH1 codon 132 mutation in brain tumors.
Jörg Balss, Jochen Meyer, Wolf Mueller, Andrey Korshunov, Christian Hartmann, Andreas von Deimling. Acta Neuropathol 2008
766
50

SEOM clinical guidelines for anaplastic gliomas (2017).
C Balañá, M Alonso, A Hernandez-Lain, A Hernandez, P Perez-Segura, E Pineda, A Ramos, A R Sanchez, P Teixidor, E Verger,[...]. Clin Transl Oncol 2018
7
50

Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.
Susan Chang, Peixin Zhang, J Gregory Cairncross, Mark R Gilbert, Jean-Paul Bahary, Carol A Dolinskas, Arnab Chakravarti, Kenneth D Aldape, Erica H Bell, David Schiff,[...]. Neuro Oncol 2017
39
50

Reoperation for recurrent high-grade glioma: a current perspective of the literature.
Shawn L Hervey-Jumper, Mitchel S Berger. Neurosurgery 2014
69
50

Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma.
G Evren Keles, Edward F Chang, Kathleen R Lamborn, Tarik Tihan, Chih-Ju Chang, Susan M Chang, Mitchel S Berger. J Neurosurg 2006
137
50

Postoperative follow-up for selected diffuse low-grade gliomas with WHO grade III/IV foci.
Amélie Darlix, Valérie Rigau, Julien Fraisse, Catherine Gozé, Michel Fabbro, Hugues Duffau. Neurology 2020
13
50

The Role and Real Effect of an Iterative Surgical Approach for the Management of Recurrent High-Grade Glioma: An Observational Analytic Cohort Study.
Maurizio Salvati, Alessandro Pesce, Mauro Palmieri, Giacoma Maria Floriana Brunetto, Antonio Santoro, Alessandro Frati. World Neurosurg 2019
11
50

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
Martin J van den Bent, Martin Klein, Marion Smits, Jaap C Reijneveld, Pim J French, Paul Clement, Filip Y F de Vos, Antje Wick, Paul J Mulholland, Martin J B Taphoorn,[...]. Lancet Oncol 2018
56
50

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.
Benjamin M Ellingson, Martin Bendszus, Jerrold Boxerman, Daniel Barboriak, Bradley J Erickson, Marion Smits, Sarah J Nelson, Elizabeth Gerstner, Brian Alexander, Gregory Goldmacher,[...]. Neuro Oncol 2015
311
50

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development.
Juan Huang, Jialong Yu, Lin Tu, Nanqu Huang, Hang Li, Yong Luo. Front Oncol 2019
57
50

Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.
Yuxiang Wang, Aaron T Wild, Sevin Turcan, Wei H Wu, Carlie Sigel, David S Klimstra, Xiaoxiao Ma, Yongxing Gong, Eric C Holland, Jason T Huse,[...]. Sci Adv 2020
41
50

Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Fumi Higuchi, Hiroaki Nagashima, Jianfang Ning, Mara V A Koerner, Hiroaki Wakimoto, Daniel P Cahill. Clin Cancer Res 2020
49
50

Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Tomohiro Kawaguchi, Yukihiko Sonoda, Ichiyo Shibahara, Ryuta Saito, Masayuki Kanamori, Toshihiro Kumabe, Teiji Tominaga. J Neurooncol 2016
82
50

Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases.
Masayuki Kanamori, Toshihiro Kumabe, Ichiyo Shibahara, Ryuta Saito, Yoji Yamashita, Yukihiko Sonoda, Hiroyoshi Suzuki, Mika Watanabe, Teiji Tominaga. Brain Tumor Pathol 2013
16
50


Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas.
Kenneth B Fallon, Cheryl A Palmer, Kevin A Roth, L Burton Nabors, Wenquan Wang, Mark Carpenter, Ruma Banerjee, Peter Forsyth, Keith Rich, Arie Perry. J Neuropathol Exp Neurol 2004
156
50

PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities.
Hao-Wen Sim, Evanthia Galanis, Mustafa Khasraw. Cancers (Basel) 2022
7
50

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.
Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Rohrberg, Sant P Chawla, Filip Janku, David Schiff, Volker Heinemann, Yoshitaka Narita, Heinz-Josef Lenz,[...]. Clin Cancer Res 2021
19
50

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Bin Fan, Ingo K Mellinghoff, Patrick Y Wen, Maeve A Lowery, Lipika Goyal, William D Tap, Shuchi S Pandya, Erika Manyak, Liewen Jiang, Guowen Liu,[...]. Invest New Drugs 2020
52
50


Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Michael Brada, Sally Stenning, Rhian Gabe, Lindsay C Thompson, David Levy, Roy Rampling, Sara Erridge, Frank Saran, Rao Gattamaneni, Kirsten Hopkins,[...]. J Clin Oncol 2010
167
50

Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
Wolfgang Wick, Patrick Roth, Christian Hartmann, Peter Hau, Makoto Nakamura, Florian Stockhammer, Michael C Sabel, Antje Wick, Susanne Koeppen, Ralf Ketter,[...]. Neuro Oncol 2016
130
50


Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Catherine H Han, Tracy T Batchelor. Chin Clin Oncol 2017
18
50

Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas.
Marco Rossi, Lorenzo Gay, Federico Ambrogi, Marco Conti Nibali, Tommaso Sciortino, Guglielmo Puglisi, Antonella Leonetti, Cristina Mocellini, Manuela Caroli, Susanna Cordera,[...]. Neuro Oncol 2021
32
50

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
Andrew B Lassman, Fabio M Iwamoto, Timothy F Cloughesy, Kenneth D Aldape, Andreana L Rivera, April F Eichler, David N Louis, Nina A Paleologos, Barbara J Fisher, Lynn S Ashby,[...]. Neuro Oncol 2011
115
50

Treatment of anaplastic gliomas: evidences and controversies.
Marjolein Geurts, Tom J Snijders, Martin J van den Bent. Curr Opin Oncol 2021
2
50

Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.
David Schiff, Martin Van den Bent, Michael A Vogelbaum, Wolfgang Wick, C Ryan Miller, Martin Taphoorn, Whitney Pope, Paul D Brown, Michael Platten, Rakesh Jalali,[...]. Neuro Oncol 2019
49
50

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
W K Yung, M D Prados, R Yaya-Tur, S S Rosenfeld, M Brada, H S Friedman, R Albright, J Olson, S M Chang, A M O'Neill,[...]. J Clin Oncol 1999
602
50

Lower Grade Gliomas.
Gilbert Youssef, Julie J Miller. Curr Neurol Neurosci Rep 2020
30
50

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
50

Hippo Pathway in Regulating Drug Resistance of Glioblastoma.
Giacomo Casati, Laura Giunti, Anna Lisa Iorio, Arianna Marturano, Luisa Galli, Iacopo Sardi. Int J Mol Sci 2021
2
50

Serpin peptidase inhibitor, clade A member 3 (SERPINA3), is overexpressed in glioma and associated with poor prognosis in glioma patients.
Dingyuan Luo, Wei Chen, Yun Tian, Junliang Li, Xinke Xu, Cheng Chen, Fangcheng Li. Onco Targets Ther 2017
20
50

Maftools: efficient and comprehensive analysis of somatic variants in cancer.
Anand Mayakonda, De-Chen Lin, Yassen Assenov, Christoph Plass, H Phillip Koeffler. Genome Res 2018
50

Radioresistance in Glioblastoma and the Development of Radiosensitizers.
Md Yousuf Ali, Claudia R Oliva, Abu Shadat M Noman, Bryan G Allen, Prabhat C Goswami, Yousef Zakharia, Varun Monga, Douglas R Spitz, John M Buatti, Corinne E Griguer. Cancers (Basel) 2020
37
50

Molecular Characterization and Clinical Relevance of ANXA1 in Gliomas via 1,018 Chinese Cohort Patients.
Zenghui Qian, Wenhua Fan, Fanlin Meng, Zhiyan Sun, Guanzhang Li, You Zhai, Yuanhao Chang, Changlin Yang, Fan Zeng, Ruichao Chai,[...]. Front Cell Dev Biol 2021
3
50

Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review.
Margriet IJzerman-Korevaar, Tom J Snijders, Alexander de Graeff, Saskia C C M Teunissen, Filip Y F de Vos. J Neurooncol 2018
36
50

Dynamics of cancer progression.
Franziska Michor, Yoh Iwasa, Martin A Nowak. Nat Rev Cancer 2004
231
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.